Clinical Trials Logo

Clinical Trial Summary

The cross-sectional study aims to describe the burden of late effects and survivorship-specific health-related quality of life in a nationwide cohort of patients treated with allo-HSCT in Denmark. Further, identify demographic, medical or personal factors associated with better self-reported health and quality of life.


Clinical Trial Description

Objective The cross-sectional study aims to describe the burden of late effects and survivorship-specific health-related quality of life in a nationwide cohort of patients treated with allo-HSCT in Denmark. Further, identify demographic, medical or personal factors associated with better self-reported health and quality of life. Method An observational, descriptive, cross-sectional study using clinical data and self-reported questionnaires to assess the occurrence of comorbidities and self-reported late effects in survivors treated with allo-HSCT in Denmark between 1970 and 2024. Study population All survivors treated for malignant or non-malignant hematological disease with allo-HCST at the age of 18-79 years from 1970-2024 in Denmark are eligible (n=1.436). Endpoints - Self-reported survivorship specific HRQoL measured by EORTC-QOL- Survivorship 100. - Degree of health literacy measured by the Health Literacy Questionnaire (HLQ). - Occurrence or degree of Chronic Graft Versus Host Disease measured by modified Lee Chronic Graft versus host disease Symptom Scale. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06277479
Study type Observational
Source Rigshospitalet, Denmark
Contact
Status Enrolling by invitation
Phase
Start date March 2024
Completion date September 2024

See also
  Status Clinical Trial Phase
Recruiting NCT02240992 - MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment Phase 2/Phase 3
Recruiting NCT02241031 - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Phase 2/Phase 3
Completed NCT02483325 - Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases Phase 2
Recruiting NCT05041933 - Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting
Completed NCT00675038 - Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload N/A
Active, not recruiting NCT03745287 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease Phase 2/Phase 3
Recruiting NCT05505760 - Testing Content Delivery Models for MomConnect N/A
Recruiting NCT00884364 - Exercise During Chemotherapy for Patients With Hematological Malignancies Phase 3
Recruiting NCT01160952 - Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation Phase 2
Completed NCT00892502 - Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? N/A
Active, not recruiting NCT00838643 - Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) N/A
Recruiting NCT05329649 - Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) Phase 3
Not yet recruiting NCT06281496 - AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT02661035 - Allo HSCT Using RIC for Hematological Diseases Phase 2
Completed NCT00956358 - Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation N/A
Completed NCT01344681 - Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases Phase 2
Recruiting NCT02083731 - MSC for Treatment of CMV Infection Phase 2
Recruiting NCT02083718 - Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function Phase 2
Recruiting NCT01763099 - Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure Phase 2
Recruiting NCT01763086 - Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant Phase 2